title: Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
abstract: OBJECTIVE
  To determine the short-term effects of single-dose intravitreal bevacizumab injection on central corneal thickness (CCT), simulated keratometry (Sim K), anterior chamber depth (ACD), iridocorneal angle (ICA) and intraocular pressure (IOP) measurements.
  
  
  METHODS
  Prospective, nonrandomized, interventional clinical trial.
  
  
  METHODS
  Forty-three eyes of 43 patients aged between 41 and 78 years (average 62 ± 13 years) received an intravitreal injection of 2.5 mg/0.1 mL bevacizumab. Patients who had not undergone additional intravitreal anti-vascular endothelial growth factor therapy within 6 months were included in the study. CCT, Sim K, ACD and ICA measurements were obtained with Sirius Topographer. IOP measurements were taken after topographic measurements with Goldmann applanation tonometer. The CCT, ACD, ICA and IOP measurements were taken before and after 3rd, 15th days and 1st month of intravitreal bevacizumab injection.
  
  
  RESULTS
  Pre- and postinjection of 3rd, 15th days and 1st month CCT (p = 0.999), Sim K (p = 0.746), ACD (p = 0.996), ICA (p = 0.632) and IOP (p = 0.707) measurements were not statistically different. Mean CCT (p = 1.000), Sim K (0.972), ACD (p = 0.998), ICA (0.667) and IOP (0.951) values were similar before and after 3rd day of bevacizumab injection. Mean CCT (p = 0.999), Sim K (p = 0.994), ACD (p = 1.000), ICA (p = 0.999) and IOP (p = 1.000) measurements were also similar before and after 15th day of injection. Preinjection and 1st month of postinjection CCT (p = 0.999), Sim K (p = 0.932), ACD (p = 0.998), ICA (p = 1.000) and IOP (p = 0.741) measurements did not change significantly.
  
  
  CONCLUSIONS
  Single-dose intravitreal bevacizumab injection does not affect CCT, Sim K, ACD, ICA and IOP in short-term period.
authors.affiliation: Department of Ophthalmology, School of Medicine, Adiyaman University , Adiyaman , Turkey and.
authors.forename: Mete
authors.initials: M
authors.lastname: Güler
authors.forename: Musa
authors.initials: M
authors.lastname: Capkın
authors.forename: Ali
authors.initials: A
authors.lastname: Simşek
authors.forename: Semsettin
authors.initials: S
authors.lastname: Bilak
authors.forename: Burak
authors.initials: B
authors.lastname: Bilgin
authors.forename: Ali
authors.initials: A
authors.lastname: Hakim Reyhan
authors.forename: Müge
authors.initials: M
authors.lastname: Fırat
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000867:Anterior Chamber / Q000187:drug effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003315:Cornea / Q000187:drug effects*; D063171:Corneal Pachymetry; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D007498:Iris / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011446:Prospective Studies; D041623:Tomography, Optical Coherence; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Anterior chamber depth; bevacizumab; central corneal thickness; intraocular pressure; iridocorneal angle; simulated keratometry